<p>Harvest Portfolios Group Inc. 在最近向证券交易委员会提交的 13F 文件中表示，在第四季度将其在雅培（NYSE:ABT - 免费报告）股票中的持股比例提高了 5.4%。该机构投资者在此期间购买了额外的 24,559 股后，持有 481,458 股该医疗产品制造商的股票。Harvest Portfolios Group Inc. 在雅培的持股在最近的报告期末价值为 60,322,000 美元。</p>
<ul>
<li>雅培发出健康趋势跟随信号：反弹即将来临？</li>
</ul>
<p>其他一些机构投资者和对冲基金最近也增加或减少了在该股票中的持股。Fideuram Intesa Sanpaolo Private Banking S.P.A. 在第四季度购买了价值 2,054,000 美元的雅培新股份。PNC Financial Services Group Inc. 在第四季度将其在雅培的持股增加了 1.8%。PNC Financial Services Group Inc. 现在持有 4,663,821 股该医疗产品制造商的股票，价值 584,330,000 美元，此前在此期间购买了额外的 83,377 股。Saranac Partners Ltd 在第四季度将其在雅培的持股增加了 5.5%。Saranac Partners Ltd 现在持有 4,335 股该医疗产品制造商的股票，价值 544,000 美元，此前在上个季度购买了额外的 225 股。Larson Financial Group LLC 在第四季度将其在雅培的持股增加了 5.2%。Larson Financial Group LLC 现在持有 16,866 股该医疗产品制造商的股票，价值 2,113,000 美元，此前在上个季度购买了额外的 835 股。最后，Handelsbanken Fonder AB 在第四季度将其在雅培的持股提高了 11.4%。Handelsbanken Fonder AB 现在持有 1,220,202 股该医疗产品制造商的股票，价值 152,879,000 美元，此前在此期间获得了额外的 124,733 股。机构投资者持有该公司 75.18% 的股票。</p>
<p>获取 <strong>雅培</strong> 的提醒：</p>
<h2>雅培股票上涨 1.0%</h2>
<p>NYSE:ABT 周三开盘价为 88.81 美元。雅培的 1 年低点为 81.97 美元，1 年高点为 139.06 美元。该公司的 50 日移动平均线为 98.14 美元，200 日移动平均线为 112.73 美元。该公司的市值为 1547 亿美元，市盈率为 24.88，市盈率增长比率为 1.47，贝塔值为 0.65。该公司的债务与股本比率为 0.56，流动比率为 1.39，速动比率为 1.01。</p>
<ul>
<li>雅培股票崩盘：反弹可能即将到来</li>
</ul>
<p>雅培（NYSE:ABT - 获取免费报告）最近于 4 月 16 日星期四发布了季度财报。该医疗产品制造商报告本季度每股收益为 1.15 美元，超出分析师一致预期的 1.14 美元，超出 0.01 美元。该公司本季度的收入为 111.6 亿美元，而分析师预期为 109.9 亿美元。雅培的净利润率为 13.90%，股本回报率为 17.62%。该公司本季度的收入较去年同期增长了 7.8%。在去年同期，该公司每股收益为 1.09 美元。雅培已将其 2026 财年的指导目标设定为每股收益 5.380-5.580 美元，2026 年第二季度的指导目标为每股收益 1.250-1.310 美元。整体来看，研究分析师预计雅培在当前财年将发布每股收益 5.48 美元。</p>
<h2>雅培分红公告</h2>
<p>该公司最近还宣布了季度分红，已于 5 月 15 日星期五支付。4 月 15 日星期三的股东获得每股 0.63 美元的分红。这代表着每年 2.52 美元的分红和 2.8% 的收益率。该分红的除息日为 4 月 15 日星期三。雅培的分红支付比率（DPR）为 70.59%。</p>
<h2>雅培的内部买卖</h2>
<ul>
<li>一家分红王正在打折出售：雅培实验室是医疗保健的便宜货吗？</li>
</ul>
<p>在其他雅培新闻中，副总裁 John A. Jr. Mccoy 于 3 月 2 日星期一出售了 585 股该股票。该股票以平均价格 115.58 美元出售，总交易额为 67,614.30 美元。出售后，该副总裁持有 24,628 股公司股票，价值约 2,846,504.24 美元。此交易代表其持股减少了 2.32%。该出售在向证券交易委员会的法律文件中披露，可以通过此超链接访问。此外，首席财务官 Philip P. Boudreau 于 4 月 23 日星期四购买了 2,200 股该公司的股票。该股票以每股 91.50 美元的平均成本购买，总交易额为 201,300.00 美元。交易后，首席财务官持有 2,200 股公司股票，价值约 201,300 美元。该交易使其持股增加了 ∞。该购买的 SEC 文件提供了更多信息。在过去三个月中，内部人士已出售价值 353,097 美元的 3,055 股公司股票。当前 0.46% 的股票由公司内部人士持有。</p>
<h2>华尔街分析师预测增长</h2>
<p>几位股票分析师最近对雅培的股票发表了评论。瑞银集团在 4 月 20 日的研究报告中将雅培的目标价从 158.00 美元下调至 135.00 美元，并对该股票给予了 “买入” 评级。大和证券集团在 4 月 22 日的报告中将雅培的股票评级从 “跑赢大盘” 下调至 “中性”，并设定了 92.00 美元的目标价。桑福德·伯恩斯坦在 4 月 17 日的报告中将雅培的目标价从 125.00 美元下调至 110.00 美元，并对该股票给予了 “跑赢大盘” 评级。杰富瑞金融集团在 4 月 17 日的报告中将雅培的股票目标价从 145.00 美元下调至 135.00 美元，并对该股票给予了 “买入” 评级。最后，雷蒙德·詹姆斯金融在 4 月 17 日的研究报告中将雅培的目标价从 130.00 美元下调至 115.00 美元，并对该股票给予了 “跑赢大盘” 评级。两位投资分析师对该股票给予了强烈买入评级，十九位分析师给予了买入评级，五位分析师给予了持有评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 119.43 美元。</p>
<p><strong>阅读我们对雅培的最新股票分析</strong></p>
<h2>关于雅培</h2>
<p>（免费报告）</p>
<p>雅培是一家全球医疗保健公司，总部位于伊利诺伊州的雅培公园，开发、制造和销售广泛的医疗产品和服务。雅培成立于 1888 年，通过多个业务领域运营，专注于诊断、医疗设备、营养品和成熟药品。该公司向医院、诊所、实验室、零售商和直接面向消费者的渠道提供旨在诊断、治疗和管理各种健康状况的产品。</p>
<p>在诊断方面，雅培提供实验室和现场检测平台及用于检测传染病、慢性病和生物标志物的检测方法；其 Alinity 系列仪器和快速检测解决方案就是这一能力的例子。</p>
<h2>精选文章</h2>
<ul>
<li>我们更看好的五只股票超过雅培</li>
<li>HIVE 利用电力进行人工智能转型</li>
<li>深入探讨 NVIDIA 最新的投资组合动态</li>
<li>布雷迪公司推出大规模人工智能驱动的突破</li>
<li>为什么家得宝的抛售可能成为一个巨大机会</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在雅培吗？</h2>
<p>在考虑雅培之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而雅培并不在名单上。</p>
<p>虽然雅培目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

雅培

美国医药设备 ETF - iShares

标普全球医疗股指数 ETF - iShares

标普健康医疗设备 ETF - SPDR

医疗业 ETF - SPDR

医疗业 ETF - Vanguard

<p>Harvest Portfolios Group Inc. 在第四季度将其在雅培（NYSE:ABT）的股份增加了 5.4%，目前持有 481,458 股，价值 6032 万美元。其他机构投资者也调整了他们的持股。雅培的股票开盘价为 88.81 美元，市值为 1547 亿美元。该公司报告第一季度每股收益为 1.15 美元，超出预期，并宣布季度股息为每股 0.63 美元</p>

<p>Harvest Portfolios Group Inc. boosted its stake in shares of Abbott Laboratories (NYSE:ABT - Free Report) by 5.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities &amp; Exchange Commission. The institutional investor owned 481,458 shares of the healthcare product maker's stock after buying an additional 24,559 shares during the period. Harvest Portfolios Group Inc.'s holdings in Abbott Laboratories were worth $60,322,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>Harvest Portfolios Group Inc. 在最近向证券交易委员会提交的 13F 文件中表示，在第四季度将其在雅培（NYSE:ABT - 免费报告）股票中的持股比例提高了 5.4%。该机构投资者在此期间购买了额外的 24,559 股后，持有 481,458 股该医疗产品制造商的股票。Harvest Portfolios Group Inc. 在雅培的持股在最近的报告期末价值为 60,322,000 美元。</p>
</div><ul>
<li>AbbVie Fires Healthy Trend-Following Signal: Is a Rebound Ahead?</li>
</ul>
<div class="lb-trans"><ul>
<li>雅培发出健康趋势跟随信号：反弹即将来临？</li>
</ul>
</div><p>A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Fideuram Intesa Sanpaolo Private Banking S.P.A. purchased a new stake in shares of Abbott Laboratories during the fourth quarter valued at $2,054,000. PNC Financial Services Group Inc. grew its stake in shares of Abbott Laboratories by 1.8% during the 4th quarter. PNC Financial Services Group Inc. now owns 4,663,821 shares of the healthcare product maker's stock valued at $584,330,000 after purchasing an additional 83,377 shares during the period. Saranac Partners Ltd increased its stake in shares of Abbott Laboratories by 5.5% in the 4th quarter. Saranac Partners Ltd now owns 4,335 shares of the healthcare product maker's stock worth $544,000 after purchasing an additional 225 shares in the last quarter. Larson Financial Group LLC increased its stake in shares of Abbott Laboratories by 5.2% in the 4th quarter. Larson Financial Group LLC now owns 16,866 shares of the healthcare product maker's stock worth $2,113,000 after purchasing an additional 835 shares in the last quarter. Finally, Handelsbanken Fonder AB raised its stake in Abbott Laboratories by 11.4% during the 4th quarter. Handelsbanken Fonder AB now owns 1,220,202 shares of the healthcare product maker's stock worth $152,879,000 after acquiring an additional 124,733 shares during the period. Institutional investors own 75.18% of the company's stock.</p>
<div class="lb-trans"><p>其他一些机构投资者和对冲基金最近也增加或减少了在该股票中的持股。Fideuram Intesa Sanpaolo Private Banking S.P.A. 在第四季度购买了价值 2,054,000 美元的雅培新股份。PNC Financial Services Group Inc. 在第四季度将其在雅培的持股增加了 1.8%。PNC Financial Services Group Inc. 现在持有 4,663,821 股该医疗产品制造商的股票，价值 584,330,000 美元，此前在此期间购买了额外的 83,377 股。Saranac Partners Ltd 在第四季度将其在雅培的持股增加了 5.5%。Saranac Partners Ltd 现在持有 4,335 股该医疗产品制造商的股票，价值 544,000 美元，此前在上个季度购买了额外的 225 股。Larson Financial Group LLC 在第四季度将其在雅培的持股增加了 5.2%。Larson Financial Group LLC 现在持有 16,866 股该医疗产品制造商的股票，价值 2,113,000 美元，此前在上个季度购买了额外的 835 股。最后，Handelsbanken Fonder AB 在第四季度将其在雅培的持股提高了 11.4%。Handelsbanken Fonder AB 现在持有 1,220,202 股该医疗产品制造商的股票，价值 152,879,000 美元，此前在此期间获得了额外的 124,733 股。机构投资者持有该公司 75.18% 的股票。</p>
</div><p>Get <strong>Abbott Laboratories</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>雅培</strong> 的提醒：</p>
</div><h2>Abbott Laboratories Stock Up 1.0%</h2>
<div class="lb-trans"><h2>雅培股票上涨 1.0%</h2>
</div><p>NYSE:ABT opened at $88.81 on Wednesday. Abbott Laboratories has a 1-year low of $81.97 and a 1-year high of $139.06. The company has a 50-day moving average of $98.14 and a 200 day moving average of $112.73. The firm has a market cap of $154.70 billion, a PE ratio of 24.88, a price-to-earnings-growth ratio of 1.47 and a beta of 0.65. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.39 and a quick ratio of 1.01.</p>
<div class="lb-trans"><p>NYSE:ABT 周三开盘价为 88.81 美元。雅培的 1 年低点为 81.97 美元，1 年高点为 139.06 美元。该公司的 50 日移动平均线为 98.14 美元，200 日移动平均线为 112.73 美元。该公司的市值为 1547 亿美元，市盈率为 24.88，市盈率增长比率为 1.47，贝塔值为 0.65。该公司的债务与股本比率为 0.56，流动比率为 1.39，速动比率为 1.01。</p>
</div><ul>
<li>Abbott Stock Crash: Rebound Could Be Coming Fast</li>
</ul>
<div class="lb-trans"><ul>
<li>雅培股票崩盘：反弹可能即将到来</li>
</ul>
</div><p>Abbott Laboratories (NYSE:ABT - Get Free Report) last released its quarterly earnings data on Thursday, April 16th. The healthcare product maker reported $1.15 earnings per share for the quarter, topping analysts' consensus estimates of $1.14 by $0.01. The company had revenue of $11.16 billion during the quarter, compared to analyst estimates of $10.99 billion. Abbott Laboratories had a net margin of 13.90% and a return on equity of 17.62%. The firm's revenue for the quarter was up 7.8% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.09 earnings per share. Abbott Laboratories has set its FY 2026 guidance at 5.380-5.580 EPS and its Q2 2026 guidance at 1.250-1.310 EPS. As a group, research analysts anticipate that Abbott Laboratories will post 5.48 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>雅培（NYSE:ABT - 获取免费报告）最近于 4 月 16 日星期四发布了季度财报。该医疗产品制造商报告本季度每股收益为 1.15 美元，超出分析师一致预期的 1.14 美元，超出 0.01 美元。该公司本季度的收入为 111.6 亿美元，而分析师预期为 109.9 亿美元。雅培的净利润率为 13.90%，股本回报率为 17.62%。该公司本季度的收入较去年同期增长了 7.8%。在去年同期，该公司每股收益为 1.09 美元。雅培已将其 2026 财年的指导目标设定为每股收益 5.380-5.580 美元，2026 年第二季度的指导目标为每股收益 1.250-1.310 美元。整体来看，研究分析师预计雅培在当前财年将发布每股收益 5.48 美元。</p>
</div><h2>Abbott Laboratories Dividend Announcement</h2>
<div class="lb-trans"><h2>雅培分红公告</h2>
</div><p>The business also recently announced a quarterly dividend, which was paid on Friday, May 15th. Shareholders of record on Wednesday, April 15th were given a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 2.8%. The ex-dividend date of this dividend was Wednesday, April 15th. Abbott Laboratories's dividend payout ratio (DPR) is 70.59%.</p>
<div class="lb-trans"><p>该公司最近还宣布了季度分红，已于 5 月 15 日星期五支付。4 月 15 日星期三的股东获得每股 0.63 美元的分红。这代表着每年 2.52 美元的分红和 2.8% 的收益率。该分红的除息日为 4 月 15 日星期三。雅培的分红支付比率（DPR）为 70.59%。</p>
</div><h2>Insider Buying and Selling at Abbott Laboratories</h2>
<div class="lb-trans"><h2>雅培的内部买卖</h2>
</div><ul>
<li>A Dividend King on Sale: Is Abbott Labs a Healthcare Bargain?</li>
</ul>
<div class="lb-trans"><ul>
<li>一家分红王正在打折出售：雅培实验室是医疗保健的便宜货吗？</li>
</ul>
</div><p>In other Abbott Laboratories news, VP John A. Jr. Mccoy sold 585 shares of the stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $67,614.30. Following the sale, the vice president owned 24,628 shares of the company's stock, valued at approximately $2,846,504.24. This trade represents a 2.32% decrease in their position. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which can be accessed through this hyperlink. Also, CFO Philip P. Boudreau acquired 2,200 shares of the business's stock in a transaction dated Thursday, April 23rd. The stock was purchased at an average cost of $91.50 per share, for a total transaction of $201,300.00. Following the transaction, the chief financial officer owned 2,200 shares in the company, valued at approximately $201,300. The trade was a ∞ increase in their ownership of the stock. The SEC filing for this purchase provides additional information. In the last three months, insiders have sold 3,055 shares of company stock worth $353,097. 0.46% of the stock is currently owned by company insiders.</p>
<div class="lb-trans"><p>在其他雅培新闻中，副总裁 John A. Jr. Mccoy 于 3 月 2 日星期一出售了 585 股该股票。该股票以平均价格 115.58 美元出售，总交易额为 67,614.30 美元。出售后，该副总裁持有 24,628 股公司股票，价值约 2,846,504.24 美元。此交易代表其持股减少了 2.32%。该出售在向证券交易委员会的法律文件中披露，可以通过此超链接访问。此外，首席财务官 Philip P. Boudreau 于 4 月 23 日星期四购买了 2,200 股该公司的股票。该股票以每股 91.50 美元的平均成本购买，总交易额为 201,300.00 美元。交易后，首席财务官持有 2,200 股公司股票，价值约 201,300 美元。该交易使其持股增加了 ∞。该购买的 SEC 文件提供了更多信息。在过去三个月中，内部人士已出售价值 353,097 美元的 3,055 股公司股票。当前 0.46% 的股票由公司内部人士持有。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><p>Several equities analysts have recently commented on ABT shares. UBS Group lowered their price objective on Abbott Laboratories from $158.00 to $135.00 and set a &#34;buy&#34; rating on the stock in a research report on Monday, April 20th. Daiwa Securities Group downgraded shares of Abbott Laboratories from an &#34;outperform&#34; rating to a &#34;neutral&#34; rating and set a $92.00 target price on the stock. in a report on Wednesday, April 22nd. Sanford C. Bernstein decreased their price target on Abbott Laboratories from $125.00 to $110.00 and set an &#34;outperform&#34; rating on the stock in a report on Friday, April 17th. Jefferies Financial Group cut their price target on shares of Abbott Laboratories from $145.00 to $135.00 and set a &#34;buy&#34; rating on the stock in a report on Friday, April 17th. Finally, Raymond James Financial reduced their target price on Abbott Laboratories from $130.00 to $115.00 and set an &#34;outperform&#34; rating on the stock in a research note on Friday, April 17th. Two investment analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $119.43.</p>
<div class="lb-trans"><p>几位股票分析师最近对雅培的股票发表了评论。瑞银集团在 4 月 20 日的研究报告中将雅培的目标价从 158.00 美元下调至 135.00 美元，并对该股票给予了 “买入” 评级。大和证券集团在 4 月 22 日的报告中将雅培的股票评级从 “跑赢大盘” 下调至 “中性”，并设定了 92.00 美元的目标价。桑福德·伯恩斯坦在 4 月 17 日的报告中将雅培的目标价从 125.00 美元下调至 110.00 美元，并对该股票给予了 “跑赢大盘” 评级。杰富瑞金融集团在 4 月 17 日的报告中将雅培的股票目标价从 145.00 美元下调至 135.00 美元，并对该股票给予了 “买入” 评级。最后，雷蒙德·詹姆斯金融在 4 月 17 日的研究报告中将雅培的目标价从 130.00 美元下调至 115.00 美元，并对该股票给予了 “跑赢大盘” 评级。两位投资分析师对该股票给予了强烈买入评级，十九位分析师给予了买入评级，五位分析师给予了持有评级。根据 MarketBeat 的数据，该股票目前的共识评级为 “适度买入”，平均目标价为 119.43 美元。</p>
</div><p><strong>Read Our Latest Stock Analysis on Abbott Laboratories</strong></p>
<div class="lb-trans"><p><strong>阅读我们对雅培的最新股票分析</strong></p>
</div><h2>About Abbott Laboratories</h2>
<div class="lb-trans"><h2>关于雅培</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.</p>
<div class="lb-trans"><p>雅培是一家全球医疗保健公司，总部位于伊利诺伊州的雅培公园，开发、制造和销售广泛的医疗产品和服务。雅培成立于 1888 年，通过多个业务领域运营，专注于诊断、医疗设备、营养品和成熟药品。该公司向医院、诊所、实验室、零售商和直接面向消费者的渠道提供旨在诊断、治疗和管理各种健康状况的产品。</p>
</div><p>In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.</p>
<div class="lb-trans"><p>在诊断方面，雅培提供实验室和现场检测平台及用于检测传染病、慢性病和生物标志物的检测方法；其 Alinity 系列仪器和快速检测解决方案就是这一能力的例子。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精选文章</h2>
</div><ul>
<li>Five stocks we like better than Abbott Laboratories</li>
<li>HIVE Weaponizes Power for an AI Pivot</li>
<li>A Deep Dive Into NVIDIA’s Latest Portfolio Moves</li>
<li>Brady Corp Wires Up a Massive AI-Powered Breakout</li>
<li>Why Home Depot’s Sell-Off Could Become a Huge Opportunity</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过雅培</li>
<li>HIVE 利用电力进行人工智能转型</li>
<li>深入探讨 NVIDIA 最新的投资组合动态</li>
<li>布雷迪公司推出大规模人工智能驱动的突破</li>
<li>为什么家得宝的抛售可能成为一个巨大机会</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCVA" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=ABT"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送电子邮件至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Abbott Laboratories Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在雅培吗？</h2>
</div><p>Before you consider Abbott Laboratories, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑雅培之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abbott Laboratories wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师正在悄悄建议客户现在购买的股票，以便在更广泛的市场注意到之前……而雅培并不在名单上。</p>
</div><p>While Abbott Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然雅培目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Harvest Portfolios Group Inc. 增加了其在雅培公司 $ABT 的持股